We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

2 hedge funds and large institutions have $139K invested in Phio Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.1% less ownership

Funds ownership: 1.17% → 1.07% (-0.1%)

33% less funds holding

Funds holding: 3 → 2 (-1)

42% less capital inflows, than outflows

Capital inflows: $34.2K | Capital outflows: $59K

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$34.2K

Top Sellers

Rank Fund Capital Flow
1
Panagora Asset Management
Panagora Asset Management
Massachusetts
-$34K
2
Millennium Management
Millennium Management
New York
-$16K
3
Goldman Sachs
Goldman Sachs
New York
-$9K

PHIO Hedge Fund Activity: Q4 2017 in Review

2 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2017, worth a combined $139K — up 5.3% from $132K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of PHIO and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $34.2K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $34K sold.

  • 2 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2017, down from 3 in Q3 2017.
  • Funds reported $139K of Phio Pharmaceuticals stock for Q4 2017, up 5.3% quarter-over-quarter.
  • 1 fund opened new Phio Pharmaceuticals positions in Q4 2017 and 2 closed out, a net change of -1 holder.
  • The largest Phio Pharmaceuticals buyer in Q4 2017 was Susquehanna International Group, an estimated $34.2K added.
  • The largest Phio Pharmaceuticals seller in Q4 2017 was Panagora Asset Management, an estimated $34K sold.

Based on aggregated 13F filings for Q4 2017.